Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.

Kalogirou MS, Patoulias D, Haidich AB, Akriviadis E, Sinakos E

Clinics and research in hepatology and gastroenterology11 Dec 2020Cited by 11 (Europe PMC)

PMID33309563DOI10.1016/j.clinre.2020.10.012PepBankPUB-33309563

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomised trials in adults with NAFLD, liraglutide produced a non-significant decrease in hepatic fat content compared with control.
In plain wordsIn adults with fatty liver disease, liraglutide did not clearly reduce liver fat compared with control.
Peptide
Liraglutide
Outcome
No significant changeHepatic fat content
Study
n: not reported in source
Comparator
Placebo or active comparator
Analysis
Primary
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
Liraglutide produced a non-significant decrease in HFC and ALT levels, compared to control.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched major databases and grey literature from their inception to May 2019, for RCTs comparing liraglutide with placebo or active comparator in patients with NAFLD.
Summary · context
We included five trials with 371 randomised participants in total.
Report a problemFND-3330956301
02HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomised trials in adults with NAFLD, liraglutide produced a non-significant decrease in ALT compared with control.
In plain wordsIn adults with fatty liver disease, liraglutide did not clearly lower the liver enzyme ALT compared with control.
Peptide
Liraglutide
Outcome
No significant changeAlanine aminotransferase (ALT)
Study
n: not reported in source
Comparator
Placebo or active comparator
Analysis
Primary
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
Liraglutide produced a non-significant decrease in HFC and ALT levels, compared to control.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched major databases and grey literature from their inception to May 2019, for RCTs comparing liraglutide with placebo or active comparator in patients with NAFLD.
Summary · context
We included five trials with 371 randomised participants in total.
Report a problemFND-3330956302
03HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomised trials in adults with NAFLD, liraglutide significantly reduced body mass index, mainly in patients with type 2 diabetes.
In plain wordsIn adults with fatty liver disease, liraglutide lowered body mass index compared with control, mostly in people with type 2 diabetes.
Peptide
Liraglutide
Outcome
DecreaseBody mass index
Study
n: not reported in source
Comparator
Placebo or active comparator
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
It induced a significant reduction in body mass index, primarily driven by reduction in patients with type 2 diabetes
2 context sentences(design, population, supporting numbers)
Summary · context
We searched major databases and grey literature from their inception to May 2019, for RCTs comparing liraglutide with placebo or active comparator in patients with NAFLD.
Summary · context
We included five trials with 371 randomised participants in total.
Report a problemFND-3330956303
04HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomised trials in adults with NAFLD, liraglutide did not significantly change glycated hemoglobin.
In plain wordsIn adults with fatty liver disease, liraglutide did not clearly change long-term blood sugar compared with control.
Peptide
Liraglutide
Outcome
No significant changeGlycated hemoglobin (HbA1c)
Study
n: not reported in source
Comparator
Placebo or active comparator
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
while it did not affect significantly glycated hemoglobin levels
2 context sentences(design, population, supporting numbers)
Summary · context
We searched major databases and grey literature from their inception to May 2019, for RCTs comparing liraglutide with placebo or active comparator in patients with NAFLD.
Summary · context
We included five trials with 371 randomised participants in total.
Report a problemFND-3330956304
05HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomised trials in adults with NAFLD, liraglutide did not significantly change HOMA-IR.
In plain wordsIn adults with fatty liver disease, liraglutide did not clearly change insulin resistance compared with control.
Peptide
Liraglutide
Outcome
No significant changeHOMA-IR
Study
n: not reported in source
Comparator
Placebo or active comparator
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
and Homeostatic Model Assessment of Insulin Resistance
2 context sentences(design, population, supporting numbers)
Summary · context
We searched major databases and grey literature from their inception to May 2019, for RCTs comparing liraglutide with placebo or active comparator in patients with NAFLD.
Summary · context
We included five trials with 371 randomised participants in total.
Report a problemFND-3330956305
06HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomised trials in adults with NAFLD, liraglutide significantly decreased serum triglycerides, mainly in patients with type 2 diabetes.
In plain wordsIn adults with fatty liver disease, liraglutide lowered blood triglycerides compared with control, mostly in people with type 2 diabetes.
Peptide
Liraglutide
Outcome
DecreaseSerum triglycerides
Study
n: not reported in source
Comparator
Placebo or active comparator
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
liraglutide significantly decreased serum triglyceride levels, also driven by the observed reduction in patients with type 2 diabetes
2 context sentences(design, population, supporting numbers)
Summary · context
We searched major databases and grey literature from their inception to May 2019, for RCTs comparing liraglutide with placebo or active comparator in patients with NAFLD.
Summary · context
We included five trials with 371 randomised participants in total.
Report a problemFND-3330956306
07HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomised trials in adults with NAFLD, liraglutide did not significantly affect the other lipid parameters.
In plain wordsIn adults with fatty liver disease, liraglutide did not clearly change the other blood fat measures compared with control.
Peptide
Liraglutide
Outcome
No significant changeOther lipid parameters
Study
n: not reported in source
Comparator
Placebo or active comparator
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
however it did not significantly affect the rest lipid parameters.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched major databases and grey literature from their inception to May 2019, for RCTs comparing liraglutide with placebo or active comparator in patients with NAFLD.
Summary · context
We included five trials with 371 randomised participants in total.
Report a problemFND-3330956307
08HumanSystematic reviewSafety outcome
In a meta-analysis of randomised trials in adults with NAFLD, liraglutide was associated with a higher incidence of gastrointestinal adverse events than control.
In plain wordsIn adults with fatty liver disease, liraglutide was linked to more stomach and gut side effects than control.
Peptide
Liraglutide
Outcome
IncreaseGastrointestinal adverse events
Study
n: not reported in source
Comparator
Placebo or active comparator
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Liraglutide was associated with increased incidence of gastrointestinal adverse events
2 context sentences(design, population, supporting numbers)
Summary · context
We searched major databases and grey literature from their inception to May 2019, for RCTs comparing liraglutide with placebo or active comparator in patients with NAFLD.
Summary · context
We included five trials with 371 randomised participants in total.
Report a problemFND-3330956308
09HumanSystematic reviewSafety outcome
In a meta-analysis of randomised trials in adults with NAFLD, no safety issues other than gastrointestinal adverse events were identified with liraglutide.
In plain wordsIn adults with fatty liver disease, the review found no safety issues with liraglutide besides stomach and gut side effects.
Peptide
Liraglutide
Outcome
No significant changeOther safety endpoints
Study
n: not reported in source
Comparator
Placebo or active comparator
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
while, no other safety issues were identified.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched major databases and grey literature from their inception to May 2019, for RCTs comparing liraglutide with placebo or active comparator in patients with NAFLD.
Summary · context
We included five trials with 371 randomised participants in total.
Report a problemFND-3330956309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.